Xentria is a Chicago-based biotechnology company established in 2020, dedicated to advancing drug development through meaningful patient engagement and effective partnerships within the life sciences industry. With a focus on helping early-stage products progress to clinical development, Xentria collaborates closely with academic researchers, patient communities, and biotech firms. The company is known for its lead asset, XT MAB 16, a monoclonal antibody that has received Orphan Drug Designation from the FDA and EMA for the treatment of sarcoidosis. Xentria is committed to embracing the complexities of co-development projects and fostering a robust Quality Assurance culture to ensure compliance and excellence in clinical trials.